Ahmad Almatroudi1, Honghua Hu2, Anand Deva3, Iain B Gosbell4, Anita Jacombs5, Slade O Jensen6, Greg Whiteley7, Trevor Glasbey8, Karen Vickery9. 1. Surgical Infection Research Group, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia; Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Qassim, Saudi Arabia. Electronic address: ahmad.almatroudi@students.mq.edu.au. 2. Surgical Infection Research Group, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia. Electronic address: helen.hu@mq.edu.au. 3. Surgical Infection Research Group, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia. Electronic address: anand.deva@mq.edu.au. 4. Molecular Medicine Research Group, Microbiology and Infectious Diseases Unit, School of Medicine, University of Western Sydney, Penrith, NSW 2715, Australia; Department of Microbiology and Infectious Diseases, Sydney South-West Pathology Service, Liverpool, NSW, Australia; Antimicrobial Resistance and Mobile Elements Group (ARMEG), Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia. Electronic address: I.Gosbell@uws.edu.au. 5. Surgical Infection Research Group, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia. Electronic address: anita@jacombsmed.com.au. 6. Molecular Medicine Research Group, Microbiology and Infectious Diseases Unit, School of Medicine, University of Western Sydney, Penrith, NSW 2715, Australia; Antimicrobial Resistance and Mobile Elements Group (ARMEG), Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia. Electronic address: S.Jensen@uws.edu.au. 7. Whiteley Corporation, Tomago, Newcastle, NSW 2322, Australia. Electronic address: greg@whiteley.com.au. 8. Whiteley Corporation, Tomago, Newcastle, NSW 2322, Australia. Electronic address: trevor@whiteley.com.au. 9. Surgical Infection Research Group, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia. Electronic address: karen.vickery@mq.edu.au.
Abstract
UNLABELLED: The environment has been shown to be a source of pathogens causing infections in hospitalised patients. Incorporation of pathogens into biofilms, contaminating dry hospital surfaces, prolongs their survival and renders them tolerant to normal hospital cleaning and disinfection procedures. Currently there is no standard method for testing efficacy of detergents and disinfectants against biofilm formed on dry surfaces. AIM: The aim of this study was to develop a reproducible method of producing Staphylococcus aureus biofilm with properties similar to those of biofilm obtained from dry hospital clinical surfaces, for use in efficacy testing of decontamination products. The properties (composition, architecture) of model biofilm and biofilm obtained from clinical dry surfaces within an intensive care unit were compared. METHODS: The CDC Biofilm Reactor was adapted to create a dry surface biofilm model. S. aureus ATCC 25923 was grown on polycarbonate coupons. Alternating cycles of dehydration and hydration in tryptone soy broth (TSB) were performed over 12 days. Number of biofilm bacteria attached to individual coupons was determined by plate culture and the coefficient of variation (CV%) calculated. The DNA, glycoconjugates and protein content of the biofilm were determined by analysing biofilm stained with SYTO 60, Alexa-488-labelled Aleuria aurantia lectin and SyproOrange respectively using Image J and Imaris software. Biofilm architecture was analysed using live/dead staining and confocal microscopy (CM) and scanning electron microscopy (SEM). Model biofilm was compared to naturally formed biofilm containing S. aureus on dry clinical surfaces. RESULTS: The CDC Biofilm reactor reproducibly formed a multi-layered, biofilm containing about 10(7) CFU/coupon embedded in thick extracellular polymeric substances. Within run CV was 9.5% and the between run CV was 10.1%. Protein was the principal component of both the in vitro model biofilm and the biofilms found on clinical surfaces. Continued dehydration and ageing of the model biofilm for 30 days increased the % of protein, marginally decreased gylcoconjugate % but reduced extracellular DNA by 2/3. The surface of both model and clinical biofilms was rough reflecting the heterogeneous nature of biofilm formation. The average maximum thickness was 30.74±2.1 μm for the in vitro biofilm model and between 24 and 47 μm for the clinical biofilms examined. CONCLUSION: The laboratory developed biofilm was similar to clinical biofilms in architecture and composition. We propose that this method is suitable for evaluating the efficacy of surface cleaners and disinfectants in removing biofilm formed on dry clinical surfaces as both within run and between run variation was low, and the required equipment is easy to use, cheap and readily available.
UNLABELLED: The environment has been shown to be a source of pathogens causing infections in hospitalised patients. Incorporation of pathogens into biofilms, contaminating dry hospital surfaces, prolongs their survival and renders them tolerant to normal hospital cleaning and disinfection procedures. Currently there is no standard method for testing efficacy of detergents and disinfectants against biofilm formed on dry surfaces. AIM: The aim of this study was to develop a reproducible method of producing Staphylococcus aureus biofilm with properties similar to those of biofilm obtained from dry hospital clinical surfaces, for use in efficacy testing of decontamination products. The properties (composition, architecture) of model biofilm and biofilm obtained from clinical dry surfaces within an intensive care unit were compared. METHODS: The CDC Biofilm Reactor was adapted to create a dry surface biofilm model. S. aureus ATCC 25923 was grown on polycarbonate coupons. Alternating cycles of dehydration and hydration in tryptone soy broth (TSB) were performed over 12 days. Number of biofilm bacteria attached to individual coupons was determined by plate culture and the coefficient of variation (CV%) calculated. The DNA, glycoconjugates and protein content of the biofilm were determined by analysing biofilm stained with SYTO 60, Alexa-488-labelled Aleuria aurantia lectin and SyproOrange respectively using Image J and Imaris software. Biofilm architecture was analysed using live/dead staining and confocal microscopy (CM) and scanning electron microscopy (SEM). Model biofilm was compared to naturally formed biofilm containing S. aureus on dry clinical surfaces. RESULTS: The CDC Biofilm reactor reproducibly formed a multi-layered, biofilm containing about 10(7) CFU/coupon embedded in thick extracellular polymeric substances. Within run CV was 9.5% and the between run CV was 10.1%. Protein was the principal component of both the in vitro model biofilm and the biofilms found on clinical surfaces. Continued dehydration and ageing of the model biofilm for 30 days increased the % of protein, marginally decreased gylcoconjugate % but reduced extracellular DNA by 2/3. The surface of both model and clinical biofilms was rough reflecting the heterogeneous nature of biofilm formation. The average maximum thickness was 30.74±2.1 μm for the in vitro biofilm model and between 24 and 47 μm for the clinical biofilms examined. CONCLUSION: The laboratory developed biofilm was similar to clinical biofilms in architecture and composition. We propose that this method is suitable for evaluating the efficacy of surface cleaners and disinfectants in removing biofilm formed on dry clinical surfaces as both within run and between run variation was low, and the required equipment is easy to use, cheap and readily available.
Authors: Gurpreet K Chaggar; Carine A Nkemngong; Xiaobao Li; Peter J Teska; Haley F Oliver Journal: Microbiology (Reading) Date: 2022-03 Impact factor: 2.956
Authors: Carine A Nkemngong; Maxwell G Voorn; Xiaobao Li; Peter J Teska; Haley F Oliver Journal: Antimicrob Resist Infect Control Date: 2020-08-17 Impact factor: 6.454